Clinical Trials Directory

Trials / Sponsors / BioRay Pharmaceutical Co., Ltd.

BioRay Pharmaceutical Co., Ltd.

Industry · 15 registered clinical trials — 4 currently recruiting.

StatusTrialPhaseStarted
Not Yet RecruitingClinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia
Gout and Hyperuricemia
Phase 22026-04-01
Not Yet RecruitingPhase IIa Study of BRY812 Monotherapy in Advanced Gynecological Malignancies
Advanced Gynecological Malignancies
Phase 22025-12-01
RecruitingA Study of BR111 in Patients With Advanced Malignancies
Advanced Malignancies
Phase 12025-04-24
Active Not RecruitingA Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
Primary Membranous Nephropathy
Phase 22024-11-13
TerminatedA Study of BRY805 in Participants With Advanced Solid Tumors
Advanced Solid Tumor
Phase 12024-03-13
CompletedPhase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versu
Psoriasis
Phase 12024-02-21
SuspendedA Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies
Advanced Solid Malignancies
Phase 12024-02-19
RecruitingA Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies
Advanced Malignancies
Phase 12023-10-10
TerminatedPhase I/II Clinical Study of 1A46 Drug Substance
Advanced Malignancies
Phase 12023-09-12
TerminatedA Phase I Study of BR108 in Hematological Malignancies
Hematologic Malignancy
Phase 12023-03-18
TerminatedClinical Study of BR105 Injection
Advanced Malignancies
Phase 12022-04-19
CompletedComparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection
Similarity of Pharmacokinetics and Safety
Phase 12022-04-11
CompletedA Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors
Advanced Solid Tumor
Phase 12021-08-11
TerminatedComparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection
Similarity of Pharmacokinetics and Safety
Phase 12020-10-15
Active Not RecruitingTreatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
Breast Cancer
Phase 32020-06-28